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Introduction: The administration of stem cells holds promise as a potential therapy for spinal cord injury (SCI).
Mesenchymal stem cells have advantages for clinical applications, since they can be easily obtained, are suitable for
autologous transplantation and have been previously shown to induce regeneration of the spinal cord in
experimental settings. Here we evaluated the feasibility, safety and potential efficacy of autologous transplantation
of mesenchymal stem cells in subjects with chronic complete SCI.
Method: We conducted a phase I, non-controlled study in 14 subjects of both genders aging between 18 to 65 years,
with chronic traumatic SCI (>6 months), at thoracic or lumbar levels, classified as American Spinal Injury Association
(ASIA) A - complete injury. Baseline somatosensory evoked potentials (SSEP), spinal magnetic resonance imaging
(MRI) and urodynamics were assessed before and after treatment. Pain rating was performed using the McGill
Pain Questionnaire and a visual analogue score scale. Bone marrow-derived mesenchymal stem cells were cultured
and characterized by flow cytometry, cell differentiation assays and G-band karyotyping. Mesenchymal stem cells were
injected directly into the lesion following laminectomy and durotomy.
Results: Cell transplantation was an overall safe and well-tolerated procedure. All subjects displayed variable improvements
in tactile sensitivity and eight subjects developed lower limbs motor functional gains, principally in the hip flexors. Seven
subjects presented sacral sparing and improved American Spinal Injury Association impairment scale (AIS) grades to B
or C – incomplete injury. Nine subjects had improvements in urologic function. One subject presented changes
in SSEP 3 and 6 months after mesenchymal stem cells transplantation. Statistically significant correlations between
the improvements in neurological function and both injury size and level were found.
Conclusion: Intralesional transplantation of autologous mesenchymal stem cells in subjects with chronic, complete
spinal cord injury is safe, feasible, and may promote neurological improvements.
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Severe spinal cord injury (SCI), leading to chronic para-
plegia, is considered an irreversible condition for which
there is currently no effective clinical therapy [1]. The
main goal of stem cell therapy in SCI is to repair the dam-
aged neuronal tissue. In experimental models of SCI, stem
cell transplantation has been used as a new strategy to
overcome physical disability and promote neurological im-
provements. Several studies have indicated a beneficial role
for transplantation of different cell types, including bone
marrow cells, neural progenitor cells and olfactory en-
sheathing cells, into the injured spinal cord [2-6]. Another
approach that has been tested is the use of oligodendrocyte
progenitor cells to promote oligodendrogenesis after
SCI, which led to remyelinization and motor function
improvement [7].
Results in preclinical studies have encouraged researchers
to undertake clinical trials in SCI with cell therapy, mainly
with mesenchymal stem cells (MSCs), Schwann cells and
human olfactory ensheathing glia (reviewed in [8]). Special
attention has been given to MSCs, which are shown to pro-
mote neural repair and regeneration of damaged areas in
different experimental models [9-12]. MSCs exhibit a broad
degree of plasticity, with the ability to differentiate not only
into multiple mesodermal lines, including bone, fat, muscle,
liver and cartilage cells [13-17], but also into cells express-
ing neural and glial lineage markers [18,19]. In addition, it
has been reported that MSCs secrete cytokines and growth
factors that promote autocrine and paracrine effects, such
as immunosuppression, inhibition of gliosis and apoptosis,
enhanced angiogenesis, axon sorting and myelination
[20,21]. In previous studies, we have established a proto-
col for MSC intralesional transplantation in dogs and cats
with naturally acquired SCI [22,23].
Clinical use of MSCs presents several advantages, in-
cluding easy isolation from bone marrow aspirates and
large-scale expansion in culture, allowing autologous
transplantations [18,22]. Moreover, to date, in vivo tumor
development has not been reported, either in experimental
models or in clinical trials in which MSCs were used to
treat SCI [23-25]. We conducted a clinical trial to evaluate
the safety and potential efficacy of autologous bone mar-
row MSC transplantation in subjects with chronic thoracic
and lumbar SCI caused by trauma.
Methods
Ethics statement
This phase I, nonrandomized, uncontrolled, prospective,
open-label study was approved by the Brazilian National
Council of Ethics in Research (CONEP) [registration
number 14942, SIPAR/MS: 25000.112358/2008–71] and
was registered on the National Institute of Health database
[ClinicalTrials.gov:NCT01325103] [26]. Ethical guide-
line provisions from the Helsinki Declaration were followed.Written consent for participation and for publication was
obtained from the subjects.
Objectives and outcomes
The main objective was to evaluate the safety of autolo-
gous bone marrow MSC transplantation in subjects with
chronic traumatic SCI. The secondary objective was to
assess potential efficacy, through neurological improve-
ments in sensory and motor assessment (measured by
American Spinal Injury Association (ASIA) scores), pain
scores, urodynamic studies and evoked potential studies.
The safety outcome was defined as deleterious modifica-
tions on resonance magnetic imaging, as well as possible
side effects and adverse events related to the protocol pro-
cedures. The primary outcome was defined as neuro-
logical improvements on ASIA scores (light touch, pin
prick and motor power), as described previously [27]. The
secondary outcomes were defined as improvements on
pain scores, urodynamic study and evoked potential
somatosensory test. The subjects were followed up to
6 months postoperatively. All data were collected person-
ally by the same researchers, through specific forms and
validated questionnaires, in order to enhance the quality
of measurements and results.
Subject selection
Fourteen subjects who fit the following inclusion criteria
were recruited: traumatic SCI at the thoracic or lumbar
level, American Spinal Injury Association impairment
scale (AIS) grade A, age ≥18 and ≤65 years, and previous
surgical intervention for spinal cord decompression and
stabilization. The sample size was determined as the
minimal number of subjects necessary to evaluate the
procedure safety. All data were collected at Hospital São
Rafael and Hospital Espanhol in Salvador, Bahia, Brazil.
Exclusion criteria were anatomical transection of the
spinal cord, open SCI (for example, stabbing, gunshot
wound), concurrent infectious disease, terminal illness,
neurodegenerative disorders, primary hematological dis-
orders, osteopathies, coagulopathies, hepatic dysfunction,
other clinical complications that could contraindicate the
surgery, use of metallic implants that contraindicate mag-
netic resonance imaging (MRI) and participation in other
clinical trials.
Participants and researchers, those administering the
interventions and those assessing the outcomes, were
not blinded to study condition assignment.
Isolation of bone marrow cells and mesenchymal stem
cell culture
Before the procedure, subjects were assessed for hematology,
blood biochemistry, urine microbiology and screening for
HIV, human T-cell lymphotropic virus, Chagas disease, and
hepatitis B and C status. Bone marrow aspiration was
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sedated prior to the procedure and monitored by an
anesthesiologist. After local anesthesia using 2% lidocaine,
approximately 60 ml bone marrow were aspirated from
the anterior and posterior iliac crest using a specific nee-
dle of bone marrow puncture of adjustable length (1.0 to
4.8 cm) and 15 gauge (Carefusion, San Diego, CA, USA)
and were collected in 20 ml syringes containing 1 ml of
5,000 UI heparin (Cristália, Itapira, Brazil). The collection
of bone marrow cells was performed by a hematologist at
Hospital São Rafael in Salvador, Bahia, Brazil.
Cell separation and culture procedures were performed
in a certified current good manufacturing practice facility
using standardized procedures. The mononuclear cell
fraction was separated from the bone marrow by cen-
trifugation under Ficoll-Hypaque gradient (GE Health-
care Life Sciences, Little Chalfont, UK) at 2,000 rpm
without a break, at room temperature, for 30 minutes.
After three washes in saline solution, cells were plated
in culture flasks (TPP, St. Louis, MO, USA) at a density
of 1.3 × 105 cells/cm2. The cells were cultured in mini-
mum essential Eagle’s medium with alpha modifica-
tions supplemented with L-glutamine (2 mM/l), 1%
gentamycin, 2.4 g/l Hepes, 2 g/l sodium bicarbonate
(all from GIBCO, Grand Island, NY, USA) and enriched
with 15% fetal bovine serum (Hyclone/Thermo Scientific,
Logan, UT, USA). One-half of the medium was exchanged
every 3 days. Once the cells achieved 80 to 90% conflu-
ence, they were dissociated with 0.25% porcine trypsin/
0.53 mM ethylenedinitrilotetraacetic acid (Invitrogen/Life
Technologies, Grand Island, NY, USA) and replated at a
density of 8,000 cells/cm2. MSCs were expanded for
approximately 4 weeks until adequate transplantation
numbers were achieved. Confluent autologous MSCs
at passages 3 to 5 were resuspended in saline solution
containing 20% human serum albumin (CSL Behring, King
of Prussia, PA, USA). MSC suspensions (1 × 107 cells/ml)
were transferred into 1 ml syringes for local injection in sub-
jects. Before transplantation, the cells were characterized by
flow cytometry analysis, differentiation assays and G-band
karyotype analysis and tested for sterility.
Cell differentiation assays
To assess the differentiation potential of MSCs, 40,000 cells/ml
were cultured in 24-well plates (Greiner, Monroe, NC,
USA) with coverslips for performing morphological stud-
ies. When differentiation was initiated, the entire culture
medium was removed and replaced by induction medium
(specific for osteoblasts, adipocytes and chondrocytes) or
only minimum essential Eagle’s medium with alpha modi-
fications supplemented with 7.5% fetal bovine serum as
control. Commercial kits were used for adipogenic, chon-
drogenic and osteogenic induction media following the
manufacturer’s recommendations (StemPro adipogenesisDifferentiation Kit, StemPro Chondrogenesis Differentiation
Kit and StemPro Osteogenesis Differentiation Kit; GIBCO).
MSCs were continuously evaluated by phase-contrast mi-
croscopy during the differentiation process. Histochemical
staining was also used for cell morphology evaluation during
the differentiation process. MSCs differentiated into adipo-
cytes and their controls were stained with Sudan II for
visualization of lipid inclusions. The cells that differentiated
into chondrocytes and their controls were stained with
Alcian Blue for staining of proteoglycan deposits. Cells that
differentiated into osteoblasts and their controls were
stained with Von Kossa for visualization of mineralized
matrix. Morphological evaluation of cells was performed
using an AX70 optical microscope coupled to a digital
camera for imaging capture (Olympus, Tokyo, Japan).
Flow cytometry analysis
For immunophenotyping, adherent MSCs were detached
with 0.25% porcine trypsin solution (Invitrogen), washed
with saline and incubated at 4°C for 30 minutes with the
following antibodies: fluorescein isothiocyanate anti-human
CD31, phycoerythrin anti-human CD34, phycoerythrin
anti-human CD117, phycoerythrin anti-human CD14,
allophycocyanin anti-human CD90, phycoerythrin anti-
human CD79a, allophycocyanin anti-human CD44, peridi-
nin chlorophyll protein anti-human CD45, fluorescein
isothiocyanate anti-human CD19 (all from BD-Pharmingen,
San Diego, CA, USA) and fluorescein isothiocyanate anti-
human CD105 (R&D Systems, Minneapolis, MN, USA).
The acquisition and analysis were carried out using a LSR
Fortessa cytometer with the FACSDiva software (Becton
Dickinson, San Jose, CA, USA). At least 10,000 events were
collected.
Cytogenetic evaluation
Cytogenetic analysis was performed in MSC samples
from all subjects, during every passage. All of the ana-
lyses were performed prior to transplantation in order to
detect possible chromosomal mutations induced by cul-
ture conditions. MSCs were treated with 16 μg/ml colchi-
cine (Cultilab, Campinas, Brazil) for a period of 6 hours for
cell cycle arrest at metaphase. Cells were trypsinized, resus-
pended, centrifuged, exposed to hypotonic solution of
0.075 M KCl, placed in a water bath at 37°C for 30 minutes
and fixed with Carnoy’s solution 3:1 (acetic acid:methanol).
Cytogenetic analysis was performed by the GTG band-
ing technique. G bandings for the prepared slides were
aged at 60°C overnight and subjected to treatment with
a solution of 0.1% trypsin/phosphate-buffered saline and
subsequently stained with Giemsa solution/phosphate-
buffered saline. Twenty cells were analyzed for each pas-
sage. The analysis of these cells was performed using a
BX61 microscope (Olympus) and images were captured
using a digital imaging system (Applied Spectral Imaging,
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were interpreted according to the International System for
Human Cytogenetic Nomenclature classification.
Cell transplantation and subject follow-up
Subjects in the prone position under general anesthesia
underwent a midline incision comprised of two levels
above and two levels below the injury. Following lamin-
ectomy and decompression of the injured spinal canal
segment, the dura mater was opened under the micro-
scope to visualize the injured spinal segment. A fixed
cell number (5 × 106 cells/cm3) was injected per lesion
volume. The estimation of lesion volume was performed
by MRI analysis, using the ellipsoid formula, as de-
scribed previously [28].
The injection was performed over a period of 5 minutes.
Punctures were made in the cardinal directions of the in-
jured area and one level above and below, before closing
the dura mater. The whole procedure was performed only
once, by a neurosurgeon, at Hospital Espanhol in Salvador,
Bahia, Brazil.
As an incentive strategy, in order to increase compli-
ance, subjects underwent rehabilitation for 6 months
after the surgery, five times a week, for 4 hours a day
during the first 2 months and 2 hours a day in the sub-
sequent months. Regular clinical and neurological as-
sessments were performed for at least 6 months. At each
follow-up, a complete clinical assessment, neurological
evaluation and AIS scale assessment were conducted. A
urodynamic study, somatosensory evoked potentials (SSEP)
and MRI of the spine were carried out in months 3
and 6 of follow-up.
Clinical pain measures
All pain measurements were performed in a quiet room
with the temperature maintained between 21 and 23°C.
At the time of testing, subjects rated their present pain
using an unanchored visual analogue score (VAS). Data
from the VAS scale were presented in millimeters. Next,
subjects were asked to indicate where they were cur-
rently experiencing chronic pain by shading in the areas
on a drawing of the dorsal and frontal views of the hu-
man body. Following this, subjects were also asked to fill
in a standard Brazilian-Portuguese language version of
the McGill Pain Questionnaire [29], the results of which
were then quantified using the pain rating index [30].
Sensory assessment
Test sites were identified based on anatomical landmarks
to ensure that the same site could be accurately located in
subsequent sessions. For each participant, a starting
stimulation site was selected based on each individual’s
level of injury, as determined by the ASIA scale. The
starting site was defined as areas at least four dermatomesabove the neurological level of injury, where sensation was
expected to be within normal limits. The mechanical
stimulation response was measured with calibrated von
Frey filaments (Touch Test Sensory Evaluator; Stoelting,
Wood Dale, IL, USA). Each subject was instructed to close
his or her eyes during this portion of the testing and re-
spond with ‘yes’ if he or she could feel the test stimulus
when it was delivered or with ‘no’ if he or she could not
feel the stimulus. For each trial, the monofilament (10 g)
was applied perpendicular to the skin surface and, once
the filament was fully bent, was held in place for approxi-
mately 1 second before being lifted off the skin. Following
a positive response, the next area below was stimulated.
Urodynamics
The urodynamic study was performed prior to and 3 to
6 months after the transplantation of MSCs. The follow-
ing parameters were measured at cystometry: maximum
bladder capacity, compliance, bladder sensation, pres-
ence of detrusor overactivity and presence of urinary
incontinence.
Compliance was measured when the bladder showed
filling ability greater than 200 ml in the absence of de-
trusor overactivity. Bladder sensation was marked as absent,
partially preserved or completely preserved, as described
previously [31].
Those subjects with micturition were also evaluated
with the pressure-flow study. For the urodynamic study,
we used Dynamed Pro-Life Technology, São Paulo, Sp,
Brazil dynapack mpx 816 equipment. For cystometry, two
plastic urethral probes were inserted into the bladder (6 Fr
to measure intravesical pressure and 8 Fr for filling). A 10
Fr rectal probe were inserted for measuring intraabdom-
inal pressure. The filling was done with distilled water at
room temperature at a rate of 40 ml/minute.
Somatosensory evoked potentials
The SSEP were evaluated before and 3 and 6 months
after MSC transplantation. The examinations were per-
formed using Neuropack M1 (Nihon Kohden, Tokyo,
Japan) four-channel equipment, with tibial nerve stimu-
lation for evaluation of the lower limbs, registration in
the popliteal fossa, lumbar (L2/3) and scalp (Cz′ to Fpz)
regions, and median nerve stimulation for evaluation of
the upper limbs, with registration at Erb’s point, cervical
C5 and scalp (C3′ to C4′). In the event that some poten-
tials were obtained, the evaluation was replicated at least
three times to assess consistency.
Statistical analyses
The individual was the smallest unit analyzed to assess
intervention effects (same from the unit of assignment).
Missing data were not used.
Table 1 Demographic, clinical and neurological features
of the subjects
Subject Months post SCI SCI level AIS grade Lesion (cm3)
1 101 T12 A 2.7
2 42 T5 A 1.0
3 36 L1 A 5.4
4 25 T12 A 5.0
5 18 T5 A 1.0
6 29 T7 A 2.7
7 91 T5 A 4.0
8 153 T12 A 4.0
9 180 T12 A 0.8
10 27 T5 A 0.9
11 52 T12 A 7.5
12 19 T7 A 10.4
13 66 T7 A 3.0
14 26 T12 A 3.0
AIS, American Spinal Injury Association impairment scale; SCI, spinal
cord injury.
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light touch and pin prick, before and 6 months after
transplantation. The nonparametric Wilcoxon signed-rank
test was employed to test the existence of a statistically sig-
nificant difference between ASIA motor scores before and
6 months after transplantation. Pearson correlation analysis
was performed to evaluate possible correlations between
ASIA scores (light touch, pin prick and motor power)
and lesion characteristics (volume, level and time of le-
sion). Statistical analyses were performed using Prism
Software (version 3.0; GraphPad Software, San Diego,




Regarding the enrollment, 555 participants were screened
for eligibility, 205 were found to be eligible and 14 were
enrolled (10 males), following the order of first contact
date. Fourteen subjects were assigned to the study condi-
tion and were submitted to bone marrow aspiration and
MSC transplantation. Of the 14 subjects assigned, two
were considered to have lost follow-up; one due to leg and
urethral injuries unrelated to the study protocol, and the
other due to lack of compliance with the assessments.
These two subjects, considered noncompliers, were ex-
cluded from the main analysis.
Subjects had chronic traumatic SCI with a mean dur-
ation of approximately 61.7 months (ranging from 18 to
180 months). Four subjects were female and 10 were
male, with mean age of 35.7 ± 9.9 years, ranging from 23
to 61. All were classified as ASIA grade A and had injur-
ies in the lumbar or thoracic segments of the spinal
cord. The lesion volumes were estimated by MRI ana-
lysis, with a mean of approximately 3.66 cm3, ranging
from 0.77 to 10.44 cm3. The demographic, clinical,
radiological and neurological features of the subjects
are presented in Table 1.
Study protocol deviations
Urodynamic data were not properly collected due to re-
current urinary infection in some of the subjects, who
could not be submitted to the urodynamic study in the
correct timeframe.
Mesenchymal stem cell characterization
Cultured bone marrow-derived cells presented a fibroblast-
like morphology and showed 97.4 ± 3.1% cells positive for
CD105, 97.5 ± 2.8% cells positive for CD73 and 96.6 ± 3.5%
cells positive for CD90. Moreover, MSC cultures presented
2.0 ± 2.1% cells positive for CD45, 2.3 ± 2.6% cells positive
for CD14, 2.4 ± 3.0% cells positive for CD79 and 2.3 ± 2.5%
cells positive for CD34. The MSCs were successfully in-
duced to differentiate into chondrocytes, osteocytes andadipocytes (Figure 1). Additionally, no chromosomal aber-
rancies were detected in G-band karyotype analysis in the
passages used for transplantation (Figure 2).
Adverse effects
Transplantation of bone marrow-derived MSCs was an
overall safe procedure. All of the subjects were dis-
charged within 48 hours after surgery. The most fre-
quent postoperative symptom was low-intensity pain at
the incision site, which was responsive to regular analge-
sics. One subject developed a postoperatory complica-
tion, evolving a cerebrospinal fluid leak that was treated
by an additional surgical procedure. None of the subjects
had fever, infection or meningitis. Subjects underwent a
program of rehabilitation beginning 1 week after the sur-
gical procedure, which was well tolerated.
Clinical assessments
Neurological evaluation revealed variable improvements
in sensitivity below the lesion level following treatment,
as assessed by light touch and pin prick (Figure 3A,B).
Light touch and pin prick ASIA sensitivity score ana-
lysis, prior to and 6 months after transplantation, dem-
onstrated a statistically significant improvement (P <0.01
and P <0.001, respectively; paired t test). All subjects
showed some degree of sensitivity gain in response to
mechanical stimulation when measured with von Frey
monofilaments (50% had significant improvements,
comparing with the presurgical profile). Subject 1
demonstrated sensitivity recovery in all dermatomes
(Table 2). Major sensitivity gains were measured in the
Figure 1 Cell differentiation assays. Mesenchymal stem cells (A) were cultured in the presence of adipogenic (B), osteogenic (C) and
chondrogenic (D) differentiation media. Cultures were stained with Sudan II, von Kossa and Alcian blue, respectively. Representative images
obtained from mesenchymal stem cell cultures from one patient. Magnification = 400×.
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Table 2). The Pearson coefficient showed an inverse cor-
relation between light touch gain 6 months after trans-
plantation and lesion volume (r2 = 0.3486; Figure 4A). No
significant correlations were observed when light touch or
pin prick sensitivity gains were analyzed in relation to level
or time of lesion.
Improvements in lower limb motor function were ob-
served in eight subjects (Figure 3C). Two subjects pre-
sented gains in hip flexor function, three subjects had
gains in knee extension movement and three subjects
demonstrated gains in ankle dorsiflexion. The most fre-
quent alteration was the increased motor power observed
in hip-related muscle groups. A statistically significant
improvement in ASIA motor scores was observed when
comparing before and 6 months after transplantation
(P <0.05; Wilcoxon signed-rank test). The Pearson coeffi-
cient demonstrated a direct correlation between motor
gain and lesion level (r2 = 0.6386) 6 months after trans-
plantation (Figure 4B). No significant correlations were
seen when motor gains were analyzed in relation to vol-
ume or time of lesion.
Additionally, seven subjects presented sacral sparing
after MSC transplantation, having recovered anal sensa-
tion. Of these, six subjects had changes in the AIS grade
to grade B and one subject to grade C (Table 3).Urological study
During the complete treatment and evaluation period,
renal function did not deteriorate in any of the subjects.
The maximum cystometric capacity changed from 203 ±
113 ml to 242 ± 146 ml, without statistical significance.
Bladder compliance improved significantly from 14.7 ±
8.2 to 25.4 ± 15.9 ml/cmH2O (P =0.02). Five subjects
who presented bladder sensation previously classified as
absent improved to present a reduced sensation. Ten
subjects began this study presenting detrusor overactiv-
ity during bladder filling; however, following MSC trans-
plantation, four of these subjects increased the filling
volume while three subjects decreased the filling volume
up to the first involuntary contraction. Throughout the
study, all subjects remained with urinary incontinence
and in need of intermittent urinary catheterization.
Radiological evaluation
Nuclear magnetic resonance images obtained before MSC
transplantation revealed the presence of spinal cord cav-
ities in eight subjects and syrinx in two subjects. Atrophy
cord areas and gliosis, as well as findings associated with
the primary surgery (that is, epidural fibrosis, soft tissue),
were found in all subjects. MRI analysis 3 and 6 months
after MSC transplantation revealed no alterations in hy-
perintense signals, extension of cavities or appearance of
Figure 2 Karyotype of bone marrow-derived mesenchymal stem cells by GTG banding. (A) Patient 7: 46,XX [20]. (B) Subject 10: 46,XY.
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mation were observed during the follow-up.
Pain assessment
Three subjects presented transient worsening of neuro-
pathic pain, which was pharmacologically controlled. Three
subjects ameliorated the neuropathic pain 3 months post
treatment, with significant reduction of pharmacological
therapy dependency.
Clinical pain measurements, administered through the
VAS and pain rating index from the McGill Pain Ques-
tionnaire, were assessed prior to and 1, 3 and 6 months
following MSC transplantation (Table 4). Although areduction in the VAS and pain rating index was ob-
served in 67% of subjects 6 months after surgery, there
were no statistically significant differences observed when
subjects were compared at 0 and 6 months after MSC
transplantation (P = 0.0538 and P = 0.1211, respectively;
paired t test).
Somatosensory evoked potential
Subjects were assessed for SSEP before, 3 and 6 months
after MSC transplantation. Lower sensory nerve electrical
stimulation-mediated SSEP were not evoked in any subject
prior to transplantation. Only one subject (Subject 14) pre-
sented an improved SSEP response in the left side 3 months
Figure 3 American Spinal Injury Association scores before and
during follow up. Sensory scores evaluated by the light touch (A) and
pin prick (B). American Spinal Injury Association (ASIA) motor score (C).
Table 2 Response to mechanical stimulation
Subject
number






1 T11/T11 L1/L1 ALL ALL
4 L2/L2 L2/L3 L3/S2 S2/S2
5 T4/T4 T4/T4 T5/T4 T5/T4
6 T5/T4 T5/T5 T6/T5 T6/T6
7 T4/T3 T5/T4 T5/T4 T5/T4
8 T11/T11 T12/T12 T12/T12 T12/T12
9 T12/L1 L3/L3 L3/L3 L3/L3
10 T5/T5 T5/T6 T6/T6 T7/T6
11 T11/L1 L1/L2 L1/L2 L2/L2
12 T4/T4 T5/T5 T6/T5 T6/T5
13 T5/T4 T7/T6 T8/T6 T7/T6
14 T11/T10 T12/T11 L1/T11 L5-S1/T12
aSide of the body (right/left).
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follow-up conclusion. Despite the fact that the SSEP re-
corded in this subject presented a low amplitude, they were
consistent and demonstrated the cortical response in P37/
N45 on the left side.
Discussion
A growing body of evidence, both experimental as well as
clinical, has demonstrated that spontaneous plasticity events
may occur within the post-traumatically injured spinal cord,
through mechanisms including alterations in the properties
of spared neuronal circuits, intact or injured axon collateral
sprouting and synaptic rearrangements, as reviewed by Oni-
fer and colleagues [32]. Nonetheless, although there is anabundance of studies describing the natural history of
neurologic functional gains during the first year post SCI,
there is a lack of data regarding the degree of neurological
recovery that may naturally occur during prolonged follow-
up investigation. A previous study described that 16.9% of
subjects with complete SCI improved motor levels between
years 1 and 5 after SCI, and went on to demonstrate an im-
provement from a complete to an incomplete injury in 5.6%
of those subjects [33].
In the present study we enrolled subjects with chronic
and complete SCI (ASIA grade A) who had previously
been subjected to decompressive surgery and lengthy re-
habilitation protocols without acquiring significant motor
or sensory gains. Locomotor training has been shown to
improve the recovery of walking in many subjects with in-
complete SCI, but not in subjects with severe injury [34].
Our primary outcome was safety, and we described ad-
verse events in only one subject who presented a cere-
brospinal fluid leak as a postoperative complication not
related to the MSCs but rather to the surgical procedure.
Cerebrospinal fluid leak is not a routine complication,
but may occur in 9% of open spine surgeries [35]. The
leak is considered a minor complication because usually
it does not change the outcome of the surgery.
Although this was not a controlled study, based on the
subject profiles and the expected spontaneous gains, our
study showed potential benefits of MSC transplantation
treatment in variable degrees of motor and sensory improve-
ments, clinical pain measures and urodynamic parameters.
Importantly, we showed that MSC transplantation resulted
in the conversion from complete to incomplete injury in
seven subjects (58.3%), which was accompanied by improve-
ment in AIS score to grade B or C.
Figure 4 Analyses of correlation between lesion characteristics and American Spinal Injury Association scores. (A) Pearson correlation
analysis of lesion volume (cm3) and light touch American Spinal Injury Association (ASIA) score. (B) Pearson correlation analysis of lesion level and
ASIA lower limb motor improvement. Lesion level was consecutively numbered starting from T1.
Table 4 Clinical pain measures
Subject VAS PRI
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SCI were not as encouraging as those demonstrated
here. A study performed with 67 subjects receiving au-
tologous MSC injections intralesionally and intrathecally
reported improvements only in one subject, which was
considered to be part of the natural history of the dis-
ease [23]. A study by Park and colleagues showed signifi-
cant improvement in three of 10 subjects submitted to
intramedullary injection, followed by intrathecal admin-
istration of MSCs [24]. Another study evaluated the poten-
tial of MSCs injected intrathecally to enhance rehabilitation
in 63 subjects with chronic SCI. In the MSC group (con-
sisting of 40 grade A subjects), 12 subjects improved their
AIS score of grade A to grade B or C (a conversion rate of
30%), with no statistically significant difference when com-
pared with the control group [36]. Karamouzian and co-
workers also tested the safety and feasibility of MSC
transplantation by lumbar puncture in 11 subjects, in a
nonrandomized clinical trial, comparing the results
with those of 20 control subjects who received conven-
tional treatment. Although five of 11 subjects (45.5%)
in the study group and three in the control groupTable 3 Summary of American Spinal Injury Association
impairment scale grades
Subject Baseline 3 months 6 months
1 A A B
4 A A A
5 A A A
6 A A A
7 A A A
8 A B B
9 A B B
10 A A B
11 A A C
12 A A A
13 A B B
14 A B B(15%) demonstrated improvements, there was no stat-
istical significance between the two groups [25].
Variability of the results may be caused by the different
numbers of cells, routes and regimen of administration.
These are considered key factors for the development of
optimized cell-based therapies [37]. The dose and ad-
ministration routes applied in the present study were
established in previous preclinical studies conducted by
our group [38,39]. Based on these preclinical studies, the
present trial was the only one to adjust the number of cells
administered into the spinal cord to the injury size esti-
mated by MRI. Moreover, considering the studies that used
intraspinal injection for MSC delivery, in the present study
the number of MSCs was considerably higher than the
others, ranging from 4 × 106 to 5 × 107 (median: 2 × 107)
versus 3× 106 to 8 × 106 [23] and 8 × 106 [24].
A recent study evaluated the outcome of 399 subjects




1 3 6 1 3 6
1 3.0 0 0 0 6.6 0 0 0
4 5.0 5.0 6.0 6.0 17.0 19.3 16.5 20.5
5 4.0 6.0 6.0 0 8.5 14.5 11.0 0
6 6.0 6.0 7.0 3.0 17.2 25.0 30.3 13
7 1.0 0 0 0 7.0 0 0 0
8 7.0 7.0 7.0 7.0 26.4 24.0 26.4 31.2
9 10.0 8.0 8.0 8.0 33.7 29.5 24.3 22.2
10 5.0 3.0 7.0 7.0 11.3 10.6 24.8 18.1
11 8.0 8.0 7.0 0 40.5 37.0 44.9 0
12 6.5 3.0 3.0 3.0 23.8 8.4 15.6 10.9
13 6.0 0 7.0 8.5 28.5 0 21.1 41.1
14 10.0 10.0 9.0 7.0 46.0 43.0 27.6 28.8
PRI: pain rating index from the McGill Pain Questionnaire; VAS, visual analogue
score for pain in millimeters.
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http://stemcellres.com/content/5/6/126between lower SCI level (T10 to T12) and improved
motor function [40]. Although the number of subjects
evaluated in our study was less than the aforementioned
investigation, we did observe a direct correlation be-
tween motor gain and injury level in SCI subjects that
received MSC transplantation. Additionally, we found an
inverse correlation between light touch gain 6 months
after transplantation and volume of the lesion. These re-
sults suggest that characteristics of the spinal cord lesion
influence the efficacy of the cell therapy, which has not
been described before.
Regarding the urodynamic study, we demonstrated a
significant enhancement in bladder compliance, which
may be an early indication of future improvements in
urinary function. Another urodynamic parameter that im-
proved in one-half of the subjects was bladder sensation,
which is critical for the subject to feel the optimal moment
to initiate bladder emptying. Improvements in bladder
sensation avoid elevated filling pressures, which are dele-
terious to the upper urinary tract. Improvement in sense
of bladder filling was seen in only one out of 13 subjects
enrolled in a previous study that evaluated the effects of
autologous MSC in subjects with chronic SCI [23].
The cell therapy protocol administered in this study
was feasible and an overall safe procedure, which capital-
ized on the use of an autologous and easily obtainable
source of cells. Importantly, our data corroborate those
obtained in previous studies, in which MSCs adminis-
tered directly into the injured spinal cord were also con-
sidered safe, even when combined with additional MSC
administrations applied by lumbar puncture [23,24].
To rehabilitate subjects bearing complete SCI for long
periods, such as those enrolled in our study, is a challen-
ging task. The loss of motor function control as a result
of interrupted pathways within the spinal cord after in-
jury has severe consequences for movement recovery,
which includes muscle atrophy, joint instability and bone
weakness. This suggests that an autologous cell therapy
approach, applied as early as possible, may be vital to
minimize the development of the deleterious secondary
outcomes following SCI and lead to an increase in likeli-
hood of motor recovery. Moreover, the combination of a
cell-based therapy with other known factors that po-
tentiate the plasticity of the central nervous system may
increase functional recovery [32]. Additionally, the level
of measurable benefits that can be achieved may depend
on several factors, including the number of MSCs injected
into the lesion site and doses, as well as therapeutic win-
dow, all of which need to be further investigated in order
to optimize the effects of MSC-based therapy for SCI.
Conclusions
The present study has demonstrated the safety, feasibility
and potential efficacy of autologous MSC administrationinto subjects with chronic SCI. Moreover, injury charac-
teristics such as level and size were found to influence the
outcome of cell therapy for SCI. The results indicate po-
tential benefits provided by MSC therapy, which should
be confirmed in larger and controlled clinical trials.
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